Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Amylyx Pharmaceuticals (AMLX) Other Operating Expenses: 2022-2024

Historic Other Operating Expenses for Amylyx Pharmaceuticals (AMLX) over the last 2 years, with Sep 2024 value amounting to $37.0 million.

  • Amylyx Pharmaceuticals' Other Operating Expenses rose 609.31% to $37.0 million in Q3 2024 from the same period last year, while for Sep 2024 it was $193.0 million, marking a year-over-year increase of 921.30%. This contributed to the annual value of $160.8 million for FY2024, which is 532.19% up from last year.
  • Per Amylyx Pharmaceuticals' latest filing, its Other Operating Expenses stood at $37.0 million for Q3 2024, which was up 22.28% from $30.3 million recorded in Q2 2024.
  • Over the past 5 years, Amylyx Pharmaceuticals' Other Operating Expenses peaked at $116.4 million during Q1 2024, and registered a low of $172,000 during Q3 2022.
  • Moreover, its 3-year median value for Other Operating Expenses was $5.6 million (2023), whereas its average is $23.6 million.
  • Data for Amylyx Pharmaceuticals' Other Operating Expenses shows a peak YoY soared of 2,933.72% (in 2023) over the last 5 years.
  • Over the past 3 years, Amylyx Pharmaceuticals' Other Operating Expenses (Quarterly) stood at $2.8 million in 2022, then skyrocketed by 231.80% to $9.4 million in 2023, then soared by 609.31% to $37.0 million in 2024.
  • Its Other Operating Expenses was $37.0 million in Q3 2024, compared to $30.3 million in Q2 2024 and $116.4 million in Q1 2024.